Scientists Block One Protein to Restore Alzheimer's Memory

Scientists at Cold Spring Harbor Laboratory just found a promising new way to fight Alzheimer's disease by targeting a protein that affects both memory and the brain's cleanup crew.

The research team discovered that blocking a protein called PTP1B significantly improved learning and memory in mice with Alzheimer's. Even better, it helped the brain's immune cells, called microglia, clear out the harmful plaque buildup that's a hallmark of the disease.

Professor Nicholas Tonks, who first discovered PTP1B back in 1988, has a personal connection to this work. His mother lived with Alzheimer's, which he describes as "a slow bereavement" where "you lose the person piece by piece."

The team found that PTP1B works by interacting with another protein called SYK, which controls how well microglia can clean up toxic debris in the brain. Graduate student Yuxin Cen explains that as Alzheimer's progresses, these cleanup cells become exhausted and less effective at their job.

What makes this discovery especially exciting is its potential to address multiple problems at once. PTP1B is already being studied as a treatment target for obesity and type 2 diabetes, both of which are major risk factors for developing Alzheimer's.

This connection could be crucial. As obesity and diabetes rates continue to rise globally, they're contributing to more Alzheimer's cases worldwide.

The Ripple Effect

Current Alzheimer's treatments mainly focus on reducing plaque buildup, but they often provide limited benefits for many patients. This new approach could change that by targeting several aspects of the disease simultaneously, offering hope for more effective treatments.

The lab is now working with a pharmaceutical company called DepYmed to develop PTP1B inhibitors. Tonks envisions combining these new drugs with existing approved treatments to create a more powerful therapy.

The goal isn't just to slow down Alzheimer's progression but to genuinely improve the quality of life for patients and their families. With PTP1B emerging as a promising target, researchers are moving closer to turning that hope into reality.